FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385380354> ?p ?o ?g. }

• W4385380354 endingPage "4235" @default.
• W4385380354 startingPage "4216" @default.
• W4385380354 abstract "Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic drugs is increasingly influencing revised recommendations for second-line therapy in type 2 diabetes (T2D). This systematic review aimed to compare the cost-effectiveness of newer antidiabetic drugs specified as sodium-glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide 1 receptor agonist (GLP-1RA), and dipeptidyl peptidase 4 inhibitor (DPP-4i) for T2D in a second-line setting. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines, and all relevant published studies were searched comprehensively in electronic databases, including PubMed, Embase, Web of Science, and International Health Technology Assessment database published from April 2023. The quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 reporting checklists. We included 28 studies that met the inclusion criteria. Overall reporting of the identified studies largely met CHEERS 2022 recommendations. The CORE and Cardiff models were the most frequently utilized for pharmacoeconomic evaluation in T2D. Four studies consistently discovered that SGLT2i was more cost-effective than GLP-1RA in T2D who were not adequately controlled by metformin monotherapy. Four studies compared GLP-1RA with DPP-4i, sufonylurea (SU), or insulin. Except for one that demonstrated SU was cost-effective, all were GLP-1RA. Five studies revealed that SGLT2i was more cost-effective than DPP-4i or SU. Eleven studies indicated that DPP-4i was more cost-effective than traditional antidiabetic drugs. Four additional studies explored the cost-effectiveness of various antidiabetic drugs as second-line options, indicating that SU, SGLT2i, or meglitinides were more economically advantageous. The most common driven factors were the cost of new antidiabetic drugs. Newer antidiabetic drugs as second line are the cost-effective option for T2D from the cost-effectiveness perspective, especially SGLT2i." @default.
• W4385380354 created "2023-07-30" @default.
• W4385380354 creator A5012413938 @default.
• W4385380354 creator A5038525695 @default.
• W4385380354 creator A5046274878 @default.
• W4385380354 creator A5061711306 @default.
• W4385380354 date "2023-07-29" @default.
• W4385380354 modified "2023-10-07" @default.
• W4385380354 title "Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review" @default.
• W4385380354 cites W1562360472 @default.
• W4385380354 cites W1678147663 @default.
• W4385380354 cites W1746290658 @default.
• W4385380354 cites W1971689005 @default.
• W4385380354 cites W1974658403 @default.
• W4385380354 cites W1981113379 @default.
• W4385380354 cites W2002269706 @default.
• W4385380354 cites W2004641751 @default.
• W4385380354 cites W2008395403 @default.
• W4385380354 cites W2054071556 @default.
• W4385380354 cites W2071835038 @default.
• W4385380354 cites W2113367996 @default.
• W4385380354 cites W2114598825 @default.
• W4385380354 cites W2132945551 @default.
• W4385380354 cites W2137746085 @default.
• W4385380354 cites W2142422409 @default.
• W4385380354 cites W2153837318 @default.
• W4385380354 cites W2398251311 @default.
• W4385380354 cites W2544388418 @default.
• W4385380354 cites W2549072544 @default.
• W4385380354 cites W2562369153 @default.
• W4385380354 cites W2753237790 @default.
• W4385380354 cites W2766166596 @default.
• W4385380354 cites W2916296804 @default.
• W4385380354 cites W2921711486 @default.
• W4385380354 cites W2969262430 @default.
• W4385380354 cites W3007686565 @default.
• W4385380354 cites W3012131422 @default.
• W4385380354 cites W3044692837 @default.
• W4385380354 cites W3046682998 @default.
• W4385380354 cites W3081345460 @default.
• W4385380354 cites W3108284480 @default.
• W4385380354 cites W3110290578 @default.
• W4385380354 cites W3111093755 @default.
• W4385380354 cites W3118615836 @default.
• W4385380354 cites W3152910579 @default.
• W4385380354 cites W3156316855 @default.
• W4385380354 cites W3206128269 @default.
• W4385380354 cites W4200026682 @default.
• W4385380354 cites W4200123307 @default.
• W4385380354 cites W4200439235 @default.
• W4385380354 cites W4206006624 @default.
• W4385380354 cites W4213122272 @default.
• W4385380354 cites W4213148026 @default.
• W4385380354 cites W4236091789 @default.
• W4385380354 cites W4308366171 @default.
• W4385380354 cites W4328051807 @default.
• W4385380354 doi "https://doi.org/10.1007/s12325-023-02612-z" @default.
• W4385380354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37515713" @default.
• W4385380354 hasPublicationYear "2023" @default.
• W4385380354 type Work @default.
• W4385380354 citedByCount "0" @default.
• W4385380354 crossrefType "journal-article" @default.
• W4385380354 hasAuthorship W4385380354A5012413938 @default.
• W4385380354 hasAuthorship W4385380354A5038525695 @default.
• W4385380354 hasAuthorship W4385380354A5046274878 @default.
• W4385380354 hasAuthorship W4385380354A5061711306 @default.
• W4385380354 hasBestOaLocation W43853803541 @default.
• W4385380354 hasConcept C112930515 @default.
• W4385380354 hasConcept C126322002 @default.
• W4385380354 hasConcept C134018914 @default.
• W4385380354 hasConcept C17744445 @default.
• W4385380354 hasConcept C177713679 @default.
• W4385380354 hasConcept C189708586 @default.
• W4385380354 hasConcept C199539241 @default.
• W4385380354 hasConcept C2777180221 @default.
• W4385380354 hasConcept C2779306644 @default.
• W4385380354 hasConcept C2779473830 @default.
• W4385380354 hasConcept C2780323712 @default.
• W4385380354 hasConcept C3019080777 @default.
• W4385380354 hasConcept C555293320 @default.
• W4385380354 hasConcept C71924100 @default.
• W4385380354 hasConcept C98274493 @default.
• W4385380354 hasConceptScore W4385380354C112930515 @default.
• W4385380354 hasConceptScore W4385380354C126322002 @default.
• W4385380354 hasConceptScore W4385380354C134018914 @default.
• W4385380354 hasConceptScore W4385380354C17744445 @default.
• W4385380354 hasConceptScore W4385380354C177713679 @default.
• W4385380354 hasConceptScore W4385380354C189708586 @default.
• W4385380354 hasConceptScore W4385380354C199539241 @default.
• W4385380354 hasConceptScore W4385380354C2777180221 @default.
• W4385380354 hasConceptScore W4385380354C2779306644 @default.
• W4385380354 hasConceptScore W4385380354C2779473830 @default.
• W4385380354 hasConceptScore W4385380354C2780323712 @default.
• W4385380354 hasConceptScore W4385380354C3019080777 @default.
• W4385380354 hasConceptScore W4385380354C555293320 @default.
• W4385380354 hasConceptScore W4385380354C71924100 @default.
• W4385380354 hasConceptScore W4385380354C98274493 @default.
• W4385380354 hasFunder F4320336309 @default.

• next